The present invention provides stable bendamustine-containing pharmaceutical compositions suitable for long term storage. The compositions include bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, a solvent mixture of N,N-dimethylacetamide and glycerin, and an antioxidant. The bendamustine-containing compositions have less than about 2% of total impurities after two month storage at 25.degree. C./60% RH. The pharmaceutical compositions may be used for treating neoplastic diseases.

Patel; Mahendra R.

Navinta, LLC

Liquid bendamustine formulation

Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.

glycerin/neoplasms

Liquid bendamustine formulation

Kit for delivering decitabine in vivo

Liquid formulation of decitabine and use of the same

Method of administering decitabine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen